The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Discovery Strengthens Board with Appointment of Dr. Ian Gilham

01 Aug 2013

Cambridge, UK 1st August 2013: Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalized medicines, has announced the appointment of Dr. Ian Gilham as a non-executive director.

Ian is currently non-executive chairman of Multiplicom NV, focused on the development and commercialization of DNA sequencing products; and Biosurfit SA, focused on development and commercialization of point-of-care diagnostic products. He is also Director of Stowheath Ltd., which offers advisory services to private equity companies and corporate finance organizations investing in clinical diagnostics and medical device companies. Ian has previously been CEO of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.

Commenting on the announcement, Dr. Darrin M Disley, CEO of Horizon said: “I would like to welcome Ian to Horizon’s board of directors. His commercial and investor relations experience will be highly valuable to the company as we continue to develop as a world-leading translational genomics organization.”

Dr. Gilham noted: “Horizon is one of the UK’s most promising life science companies. I’m delighted to join the board at this stage of the organization’s development.”

Horizon’s mission is to provide its customers with cutting-edge biological tools and services that will accelerate the pace of development of ‘personalized’ medicines.